Colloidal metal compositions and methods

Abstract

The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.

1. A composition comprising for treating a solid tumor consisting essentially of a pegylated colloidal gold particle and an anti-cancer therapeutic agent, wherein a polyethylene glycol derivative is covalently bound to the colloidal gold particle. 
     
     
       2. The composition of  claim 1 , further comprising an anticancer therapeutic agent. 
     
     
       3. The composition of claim  2  1, wherein the anti-cancer therapeutic agent comprises endostatin, angiostatin, thalidomide, taxol, melphalan, paclitaxel, taxanes, vinblastin, vincristine, doxorubicin, tumor necrosis factor, acyclovir, cisplatin or tacrine. 
     
     
       4. The composition of  claim 1 , further comprising a targeting molecule. 
     
     
       5. The composition of  claim 1 , further comprising wherein the anti-cancer therapeutic agent is bound to the colloidal gold particle by an integrating molecule. 
     
     
       6. The composition of  claim 1 , wherein the polyethylene glycol derivative is a polyethylene glycol-thiol derivative. 
     
     
       7. The composition of  claim 1 , further comprising an immunostimulating molecule. 
     
     
       8. The composition of  claim 7 , wherein the immunostimulating molecule is selected from the group consisting of Interleukin-1, Interleukin-2, Interleukin-3, Interleukin-4, Interleukin-5, Interleukin-6, Interleukin-7, Interleukin-8, Interleukin-10, Interleukin-11, Interleukin-12, Interleukin-13, lipid A, phospholipase A2, endotoxins, staphylococcal enterotoxin B, Type I Interferon, Type II Interferon, Tumor Necrosis Factor alpha, Transforming Growth Factor beta, Lymphotoxin, Migration Inhibition Factor, Granulocyte-Macrophage Colony-Stimulating Factor, Monocyte-Macrophage Colony-Stimulating Factor, Granulocyte Colony-Stimulating Factor, Angiogenin, transforming growth factor alpha, fibroblast growth factor, cancer cell specific antigens, MART, MAGE, RAGE, B7 family of molecules and receptors, CD40 ligand/receptor, basic fibroblast growth factor, and vascular endothelial growth factor. 
     
     
       9. The composition of claim 1, wherein the anti-cancer therapeutic agent is tumor necrosis factor alpha.